secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001193125-23-019083
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst completes $160M acquisition of U.S. rights to FYCOMPA from Eisai, expects accretion in 2023
--------------------------------------------------------------------------------

- Paid $160M upfront all-cash to Eisai; potential milestone/royalty payments under certain conditions.
- FYCOMPA net revenue for FY ending March 31, 2023 expected ~$136M; gross margin similar to FIRDAPSE.
- Eisai will supply FYCOMPA for 7 years and provide transition services for up to 180 days post-closing.
- Acquisition expected to be accretive to EBITDA and EPS in 2023; FIRDAPSE revenue guidance unchanged at $205-210M.
- Overlaps ~45% with FIRDAPSE physician call points; strengthens neuroscience portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/0001193125-23-019083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/d103110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-019083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer